View More Recent Stories
-
Kymera Therapeutics (KYMR) October 50 puts active on bid
-
Wolfe Research Upgrades Kymera Therapeutics (KYMR) to Outperform
-
Kymera Therapeutics (KYMR) Prices $225M Offering at $40.75/sh
-
Kymera Therapeutics (KYMR) Announces $200M Proposed Public Offering
-
Kymera Therapeutics (KYMR) PT Raised to $60 at H.C. Wainwright
-
Kymera Therapeutics (KYMR) Tops Q2 EPS by 10c
-
Kymera Therapeutics (KYMR) PT Raised to $36 at B.Riley
-
TD Cowen Reiterates Buy Rating on Kymera Therapeutics (KYMR)
-
After-hours movers: Intel, Helios, Zapp Electric Vehicles Group and more
-
Kymera Therapeutics (KYMR) Announces Expansion of KT-474 HS and AD Phase 2 Studies
-
Piper Sandler Reiterates Overweight Rating on Kymera Therapeutics (KYMR)
-
H.C. Wainwright Reiterates Buy Rating on Kymera Therapeutics (KYMR)
-
Kymera Therapeutics (KYMR) Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

